Market Cap | 837.49M | P/E | - | EPS this Y | -2.00% | Ern Qtrly Grth | - |
Income | -180.66M | Forward P/E | -4.14 | EPS next Y | -6.60% | 50D Avg Chg | -8.00% |
Sales | 26.98M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
Dividend | N/A | Price/Book | 2.86 | EPS next 5Y | - | 52W High Chg | -31.00% |
Recommedations | 1.80 | Quick Ratio | 7.92 | Shares Outstanding | 37.97M | 52W Low Chg | 23.00% |
Insider Own | 6.17% | ROA | -23.60% | Shares Float | - | Beta | 0.89 |
Inst Own | 91.75% | ROE | -56.31% | Shares Shorted/Prior | 2.54M/2.76M | Price | 23.16 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 202,477 | Target Price | 43.20 |
Oper. Margin | -1,017.35% | Earnings Date | May 2 | Volume | 317,904 | Change | -5.35% |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Needham | Buy | Apr 10, 24 |
Canaccord Genuity | Buy | Feb 21, 24 |
HC Wainwright & Co. | Buy | Feb 21, 24 |
Needham | Buy | Feb 21, 24 |
JMP Securities | Market Outperform | Dec 20, 23 |
Needham | Buy | Dec 15, 23 |
Cantor Fitzgerald | Overweight | Nov 8, 23 |
Morgan Stanley | Equal-Weight | Nov 3, 23 |
B. Riley Securities | Buy | Sep 12, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Thompson Travis Alvin | Chief Accounting Off.. Chief Accounting Officer | Jan 02 | Sell | 17.5 | 604 | 10,570 | 23,375 | 01/04/24 |
Keen Nicholas | Chief Scientific Off.. Chief Scientific Officer | Jan 02 | Sell | 17.5 | 2,640 | 46,200 | 63,593 | 01/04/24 |
Crockett Nigel | Chief Business Offic.. Chief Business Officer | Jan 02 | Sell | 17.5 | 2,643 | 46,252 | 48,716 | 01/04/24 |
Milnes Alistair | Chief Operating Offi.. Chief Operating Officer | Jan 02 | Sell | 17.5 | 2,643 | 46,252 | 73,196 | 01/04/24 |
Skynner Michael | Chief Technology Off.. Chief Technology Officer | Jan 02 | Sell | 17.5 | 2,643 | 46,252 | 95,839 | 01/04/24 |
Lee Kevin | Chief Executive Offi.. Chief Executive Officer | Jan 02 | Sell | 17.5 | 8,703 | 152,302 | 390,428 | 01/04/24 |
Thompson Travis Alvin | Chief Accounting Off.. Chief Accounting Officer | Oct 03 | Sell | 20.00 | 54 | 1,080 | 7,979 | 10/05/23 |
Keen Nicholas | Chief Scientific Off.. Chief Scientific Officer | Oct 03 | Sell | 20.00 | 272 | 5,440 | 38,233 | 10/05/23 |
Crockett Nigel | Chief Business Offic.. Chief Business Officer | Oct 03 | Sell | 20.00 | 442 | 8,840 | 29,359 | 10/05/23 |
Milnes Alistair | Chief Operating Offi.. Chief Operating Officer | Oct 03 | Sell | 20.00 | 442 | 8,840 | 36,839 | 10/05/23 |
Lee Kevin | Chief Executive Offi.. Chief Executive Officer | Oct 03 | Sell | 20.00 | 1,470 | 29,400 | 322,131 | 10/05/23 |
Skynner Michael | Chief Technology Off.. Chief Technology Officer | Oct 03 | Sell | 20.00 | 442 | 8,840 | 70,482 | 10/05/23 |
Thompson Travis Alvin | Chief Accounting Off.. Chief Accounting Officer | Jul 03 | Sell | 25.10 | 61 | 1,531 | 8,033 | 07/06/23 |
Skynner Michael | Chief Technology Off.. Chief Technology Officer | Jul 03 | Sell | 25.10 | 451 | 11,320 | 70,924 | 07/06/23 |
Milnes Alistair | Chief Operating Offi.. Chief Operating Officer | Jul 03 | Sell | 25.10 | 451 | 11,320 | 37,281 | 07/06/23 |
Lee Kevin | Chief Executive Offi.. Chief Executive Officer | Jul 03 | Sell | 25.10 | 1,498 | 37,600 | 323,601 | 07/06/23 |
Keen Nicholas | Chief Scientific Off.. Chief Scientific Officer | Jul 03 | Sell | 25.10 | 336 | 8,434 | 38,505 | 07/06/23 |
Crockett Nigel | Chief Business Offic.. Chief Business Officer | Jul 03 | Sell | 25.10 | 451 | 11,320 | 29,801 | 07/06/23 |
Crockett Nigel | Chief Business Offic.. Chief Business Officer | Jan 03 | Sell | 29.06 | 1,801 | 52,337 | 30,699 | 01/05/23 |
Milnes Alistair | Chief Operating Offi.. Chief Operating Officer | Jan 03 | Sell | 29.06 | 1,801 | 52,337 | 38,179 | 01/05/23 |
Smethurst Dominic | Chief Medical Office.. Chief Medical Officer | Jan 03 | Sell | 29.06 | 1,801 | 52,337 | 36,699 | 01/05/23 |
Skynner Michael | Chief Technology Off.. Chief Technology Officer | Jan 03 | Sell | 29.06 | 1,801 | 52,337 | 71,822 | 01/05/23 |
Keen Nicholas | Chief Scientific Off.. Chief Scientific Officer | Jan 03 | Sell | 29.06 | 1,817 | 52,802 | 39,160 | 01/05/23 |
Kalowski Lee | President and CFO President and CFO | Jan 03 | Sell | 29.06 | 1,815 | 52,744 | 30,685 | 01/05/23 |
Lee Kevin | Chief Executive Offi.. Chief Executive Officer | Jan 03 | Sell | 29.06 | 6,000 | 174,360 | 326,585 | 01/05/23 |
Legault Pierre | Director Director | Dec 20 | Option | 8.44 | 150,000 | 1,266,000 | 97,860 | 12/22/21 |
Legault Pierre | Director Director | Dec 20 | Sell | 57.38 | 150,000 | 8,607,000 | 12/22/21 | |
Lee Kevin | Chief Executive Offi.. Chief Executive Officer | Oct 14 | Sell | 60.02 | 5,000 | 300,100 | 225,085 | 10/18/21 |
Lee Kevin | Chief Executive Offi.. Chief Executive Officer | Oct 11 | Sell | 54.22 | 5,000 | 271,100 | 230,085 | 10/13/21 |
Kalowski Lee | President and CFO President and CFO | Sep 03 | Sell | 40 | 10,000 | 400,000 | 09/03/21 | |
Kalowski Lee | President and CFO President and CFO | Sep 03 | Option | 9.82 | 10,000 | 98,200 | 10,000 | 09/03/21 |